(Q30414308)

English

Identification of antigen and adjuvant doses resulting in optimal immunogenicity and antibody persistence up to 1 year after immunization with a pandemic A/H1N1 influenza vaccine in children 3 to < 9 years of age.

scientific article

Statements

Identification of antigen and adjuvant doses resulting in optimal immunogenicity and antibody persistence up to 1 year after immunization with a pandemic A/H1N1 influenza vaccine in children 3 to < 9 years of age. (English)
Cynthia Nassim
Shane Christensen
Sandra Holmes
Matthew Hohenboken
Niranjan Kanesa-Thasan

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit